Navigation Links
Attention Vical Incorporated Investors: Vical Misled Investors According to a Newly Filed Class Action
Date:11/14/2013

SAN DIEGO, Nov. 14, 2013 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Vical Incorporated (NASDAQ: VICL) has filed a federal securities fraud class action complaint in the U.S. District Court for the Southern District of California.  The complaint alleges that the company and certain of its officers violated the Securities and Exchange Act of 1934 between February, 8, 2012 and August 12, 2013 (the "Class Period").  Vical engages in the research and development of biopharmaceutical products for the prevention and treatment of serious or life-threatening diseases. Vical's lead drug candidate, Allovectin, is a Phase 3 clinical trial product to treat metastatic melanoma.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO)

Vical Accused of Misleading Investors Regarding Its Ability to Obtain FDA Approval for Allovectin

Shares of Vical fell $2.05, or 57%, to close at $1.53 on August 12, 2013, after the company announced that the top-line results from the company's Phase 3 trial of Allovectin failed to demonstrate a significant improvement over chemotherapy.

According to the complaint, the company made false and misleading statements and/or failed to disclose material adverse facts about the company's business prospects and financial condition. Specifically, the complaint alleges that, throughout the Class Period, Vical misled investors about the efficacy of Allovectin and the likelihood of its success in the Phase 3 trial.  Further, the complaint alleges that the company deliberately delayed the announcement of the results of the Allovectin trial to avoid revealing the truth to the market.

Vical Shareholders Are Encouraged to Contact Shareholder Rights Law Firm Robbins Arroyo

If you invested in Vical and would like to discuss your shareholder rights, please contact attorney Darnell R. Donahue at (800) 350-6003, DDonahue@robbinsarroyo.com, or via the information form on the firm's shareholder rights blog: http://www.robbinsarroyo.com/shareholders-rights-blog/vical-incorporated/

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law.  The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. 

Attorney Advertising. Past results do not guarantee a similar outcome.  

Contact:
Darnell R. Donahue
Robbins Arroyo LLP
DDonahue@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com


'/>"/>
SOURCE Robbins Arroyo LLP
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Snap to attention: Polymers that react and move to light
2. Patient in vegetative state not just aware, but paying attention
3. Children with diplegic and hemiplegic cerebral palsy: Who can be paid more attention by rehabilitation physicians?
4. Strax Rejuvenation Releases a New Radio Ad that is Getting a Lot of Attention from Listeners
5. Researchers uncover cellular mechanisms for attention in the brain
6. Choline intake improves memory and attention-holding capacity
7. Science academies issue G-Science statements to call world leaders attention to global challenges
8. Pay attention: How we focus and concentrate
9. Hogging the spotlight: South Farms pig gets international attention
10. Top 10 new species list draws attention to diverse biosphere
11. Groundbreaking discovery of the cellular origin of cervical cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
Breaking Biology News(10 mins):
(Date:4/27/2017)... ... 27, 2017 , ... Arrowhead Publishers is pleased to announce ... to San Diego, CA on September 27-28, 2017. Leaders from the pharmaceutical, biotech, ... in the treatment of various types of pain. There are also extended networking ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... the 2017 Borlaug CAST Communication Award goes to Jayson Lusk, a consummate communicator ... forms of media to advocate for science, as he explains how innovation and ...
(Date:4/26/2017)... ... April 26, 2017 , ... Led by ... I clinical trials comes to Tampa, San Francisco and Boston in 2017. ... FDA regulated organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., Ocular Therapeutix ...
(Date:4/26/2017)... 26, 2017  Genisphere LLC, provider of the ... a collaborative and sponsored research agreement with the ... . The overall goal of the partnership is ... 3DNA designs and formulations after in vivo ... the vasculature as well as inflammatory responses, demonstrating ...
Breaking Biology Technology: